Live
Endpoints NewsNovocure’s electric fields therapy fails key glioblastoma studyPharmaVoiceAs M&A rebounds, here’s how pharmas can prepare to seal a dealFierceBiotechKardigan buttons up $400M upsized IPO to power heart drugs toward phase 3FierceBiotechNovocure device fails to improve brain cancer patients’ survival in phase 3 testFierceBiotechNortiva purrs into action with long-acting Lynx platform salvaged from Langer startupEndpoints NewsInnoviva revives Lyndra's long-acting oral drug platformFierceBiotechBiogen inks $1B RayThera buyout to bag preclinical immunology assetsEndpoints NewsModerna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departsEndpoints NewsEli Lilly's TuneLab hits 100 members, adding Chai's AI modelsCellChloroplast sunscreening by protein condensates confers high-light tolerancePharmaVoiceA new Westlake-backed biotech takes aim at migrainesFierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test
Thermo Fisher Jan 26, 2026

Lbp Am Sa Has $131.19 Million Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Lbp Am Sa Has $131.19 Million Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Body unavailable. Use the original source.